Improve Patient outcomes
ANZIBDC member centres currently provide IBD care for ~20,000 patients which represents around 20% of the population with IBD within ANZ.
Our main focus is to improve patient outcomes and find a cure for people living with IBD.
Better Quality Clinical care
ANZIBDC, in partnership with Crohn’s Colitis Cure charity, have developed a new comprehensive cloud-based custom IBD Clinical Management Software called Crohn’s Colitis Care (CCCare).
CCCare is designed with the aim to improve quality of IBD care around Australia New Zealand by making it more consistent and evidence based; as well as assisting research by enabling better data management.
CCCare has been implemented at Royal Adelaide Hospital (SA), Liverpool Hospital (NSW) and Royal Brisbane & Women’s Hospital (QLD), and will be deployed across ANZ in 2020.
ANZIBDC has bio-specimens (DNA) stored on approximately 8000 IBD patients, which are linked to their disease behaviour and therapy over time. Each ANZIBDC site contributes patient DNA, phenotype data and biological samples (such as blood, stool and tissue samples). By pooling these resources, ANZIBDC can undertake more complex and powerful research.
ANZIBDC is a collaborative research initiative which aims to optimize patient outcomes through clinical and scientific IBD research. It was formed in 2008 and currently comprises of 14 Gastroenterology centres around Australia and New Zealand, including physicians, nurses and scientists based at these hospitals.
The ANZIBD Consortium’s major objective is to progress knowledge and clinical practice in the field of IBD through the combination of both clinical and scientific research, thus improving patient outcomes across the Australian and New Zealand populations.
ANZIBDC has also established collaborations with European and North American and Asian IBD consortia who are undertaking similar work.
Contributing to international studies and collaborating with European and North American and Asian IBD consortia and made significant contributions to several international IBD studies.